spacer
home > ebr > autumn 2009 > the biosimilars market
PUBLICATIONS
European Biopharmaceutical Review

The Biosimilars Market

 

Biosimilars, or ‘follow-on biologics’ as they are known in the US, provide access to affordable and effective medicines to patients around the world. Although the regulatory pathway put forward by the European Medicines Agency (EMEA) has facilitated the launch of a number of biosimilars, the market is still considered to be in a nascent stage. Estimates from IMS Health suggest that products worth $25 billion are expected to go off-patent by 2017, creating a significant opportunity for biosimilar players.

This article aims to set out the key challenges facing biosimilar market participants, in addition to various factors driving and restraining market growth. It also provides an overview of the competitive landscape of the current biosimilars industry and market trends.

THE ROLE OF BIOSIMILARS IN CONTROLLING PHARMACEUTICAL EXPENDITURE

One of the biggest problems facing developed economies around the world is the increase in per capita healthcare spending, which surpasses per capita income in several cases. As Figure 1 indicates, this trend is unsustainable in the long-run, and most governments have begun to take measures to ensure that spending growth falls in line with per capita income. Pharmaceutical expenditure, which is a critical component of healthcare budgets across the world, is being widely recognised as an area that needs to be controlled. This is precisely where generics and biosimilars have a crucial role to play. According to the European Generic medicines Association (EGA), generic medicines have made major contributions to affordable and accessible healthcare for over 20 years, saving the EU an estimated €20 billion annually. by 2017, creating a significant opportunity for biosimilar players.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sumanth Kambhammettu is a Programme Leader with the European Healthcare Practice of Frost & Sullivan. He focuses on analysing trends in the pharmaceutical and biotechnology markets. He has worked on various consulting projects and research reports in the areas of CNS, women’s health, cardiovascular therapeutics, generics and biosimilars, pricing and reimbursement issues, speciality pharma, stem cells, contract manufacturing organisations and several other issue-based topics. In addition, he is a regular contributor of articles on market related issues to leading industry journals. Prior to joining Frost & Sullivan, Sumanth had worked as a marketing executive with Baxter India’s renal division. Sumanth holds a B-Pharm (Hons) from the Birla Institute of Technology & Sciences (BITS), Pilani.
spacer
Sumanth Kambhammettu
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

[Noáin, April 22, 2020] 3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement